SEC Filing Analysis: Shattuck Labs, Inc. (STTK)

Executive Summary

• Trading Significance: Low
• Key Takeaway: This filing is an administrative amendment (8-K/A) to correct typographical errors in the original Q3 2025 earnings announcement. No new material information is presented.
• Market Impact: Neutral. The market has already processed the information from the original 8-K filing.

Company Information

Field	Value
Company	Shattuck Labs, Inc.
Ticker Symbol	STTK
CIK	0001680367
Industry	Pharmaceutical Preparations

Filing Details

This is a Form 8-K/A, which is a Current Report filed to provide investors with timely information about material events. This specific filing amends a prior 8-K from the same day to correct typographical errors. The substantive information relates to the company's Q3 2025 financial results and business operations, as detailed in the attached Exhibit 99.1 press release.

Financial Impact Assessment

As this filing does not report a specific transaction, a materiality analysis based on market capitalization is not applicable. The analysis focuses on the content of the announced business update.

Impact Evaluation

• Market Cap Context: Shattuck Labs is a nano-cap biotechnology company with a market capitalization of approximately $100 million. For companies of this size, news regarding clinical trial progress and financing is highly material.
• Financial Position: The press release notes cash and short-term investments of $86.1 million as of September 30, 2025. The company also closed a private placement of up to $103 million in August 2025, providing a cash runway expected to last into 2029, assuming full warrant exercise. This strong capital position is a significant de-risking event for a clinical-stage company.
• Operational Progress: The initiation of dosing in the Phase 1 trial for SL-325 is a key operational milestone, moving its lead asset forward.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This filing is a correction and contains no new information beyond the original 8-K filed earlier the same day. Therefore, no market reaction is expected from this specific amendment.

Volume & Sentiment

• Expected Volume Impact: None. The filing is administrative in nature.
• Sentiment Indicator: Neutral. The sentiment was established by the original earnings release; this amendment does not alter it.

Additional Context

Transaction Notes

• Filing Type: Form 8-K/A (Amendment to a Current Report).
• Purpose: To correct typographical errors in the original report concerning Q3 2025 financial results.
• Key Information: The substantive news remains the company's financial health, the closing of a significant private placement, and the clinical progress of its lead candidate, SL-325.